Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial

HIV Medicine

Volumn 14, Issue 7, 2013, Pages 437-444

  Sension, M ^a   Cahn, P ^b   Domingo, P ^c   Hodder, S ^d   Opsomer, M ^e   Lathouwers, E ^e   Van de Casteele, T ^e   Tomaka, F ^f  

^a Comprehensive Care Center ^*  (United States)

^b Huesped Foundation   (Argentina)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Darunavir; Efficacy; HIV; Once daily; Treatment experienced

Indexed keywords

DARUNAVIR PLUS RITONAVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DOSAGE SCHEDULE COMPARISON; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE;

DARUNAVIR; EFFICACY; HIV; ONCE DAILY; TREATMENT-EXPERIENCED;

ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; RITONAVIR; SULFONAMIDES; VIRAL LOAD; YOUNG ADULT;

EID: 84879838752     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12024     Document Type: Article

References (26)

1. Madruga JV, Berger D, McMurchie Metal. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370: 49-58.
2. Arastéh K, Yeni P, Pozniak Aetal. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther 2009; 14: 859-864.
3. Haubrich R, Berger D, Chiliade Petal. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21: F11-F18.
4. Katlama C, Esposito R, Gatell JMetal. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21: 395-402.
5. Mills AM, Nelson M, Jayaweera Detal. Once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23: 1679-1688.
6. Ortiz R, Dejesus E, Khanlou Hetal. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-1397.
7. PREZISTA® (darunavir). EPARs for authorised medicinal products for human use. Updated 22 January 2013. Available at www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000707/human_med_000988.jsp&mid=WC0b01ac058001d124 (accessed 27 February 2013).
8. PREZISTA® (darunavir). Full prescribing information. Tibotec Inc. Revised February 2013. Available at www.prezista.com/sites/default/files/pdf/us_package_insert.pdf (accessed 27 February 2013).
9. Cahn P, Fourie J, Grinsztejn Betal. ODIN: 48-week analysis of once- versus twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 2011; 25: 929-939.
10. De Meyer S, Dierynck I, Lathouwers Eetal. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2. 16th International HIV Drug Resistance Workshop. Sitges, Spain, June 2008 [Abstract 31].
11. Johnson VA, Brun-Vezinet F, Clotet Betal. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17: 138-145.
12. Johnson VA, Brun-Vezinet F, Clotet Betal. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16: 138-145.
13. King MS, Lawal AA, Fredrick LMetal. Impact of baseline resistance on virologic outcome with once-daily (QD) or twice-daily (BID) lopinavir/ritonavir (LPV/r) through 48 weeks of combination antiretroviral therapy in treatment-experienced, HIV-1-infected subjects. 12th European AIDS Conference. Cologne, Germany, November 2009 [Abstract PE10.1/1].
14. De La Rosa G, Pattery T, Picchio Getal. Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009. 10th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2010 [Abstract P132].
15. Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated 12 February 2013; 1-166.
16. Powderly WG, Saag MS, Chapman Setal. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13: 1873-1880.
17. Vray M, Meynard JL, Dalban Cetal. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther 2003; 8: 427-434.
18. Berger DS, Northland R, Scribner Aetal. Effect of baseline factors on virological response to darunavir/r and lopinavir/r at Week 48 in TITAN. 11th European AIDS Conference. Madrid, Spain, October 2007 [Abstract P7.3/27].
19. Weintrob AC, Grandits GA, Agan BKetal. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr 2009; 52: 574-580.
20. Dierynck I, De Meyer S, Lathouwers Eetal. Comparable in-vitro susceptibility and virologic outcome to darunavir in patients infected with subtype B and subtype non-B HIV isolates participating in the ARTEMIS Phase III trial. XVIIth International AIDS Conference. Mexico City, Mexico, August 2008 [Abstract TUPE0049].
21. De Meyer S, Hill A, Picchio Getal. Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial. J Acquir Immune Defic Syndr 2008; 49: 563-564.
22. Molina J-M, Cohen C, Katlama Cetal. Safety and Efficacy of Darunavir (TMC114) with low-dose Ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007; 46: 24-31.
23. Maroldo L, Lawal A, Rivero Retal. Effect of the M184V/I mutation and other nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations on virologic response to a lopinavir/ritonavir-based regimen. XVIII International AIDS Conference. Vienna, Austria, July 2010 [Abstract TUPE0119].
24. Miller V, Stark T, Loeliger AEetal. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med 2002; 3: 135-145.
25. Whitcomb JM, Parkin NT, Chappey Cetal. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188: 992-1000.
26. Paterson DL, Swindells S, Mohr Jetal. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.